RxDoctor Payments Data

Ronald Kantola, DO

Cardiology · Fort Smith, ARNPI 1265412506

Payments from drug & device makers

$16,264in general payments, 2019–2025

Across 536 payments — averaging $30.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$6K
  • Medtronic$2K
  • Novartis$2K
  • Johnson & Johnson$1K
  • Amgen$894
  • Boehringer Ingelheim$734
  • plus $3K from 22 others

What the payments were for

  • Travel & lodging$2,64116%
  • Food & beverage$13,31982%
  • Education$3042%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few cardiology providers in Arkansasto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$450,769
Medicare patients
1,185
Services billed
5,590

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban629$684,917
EntrestoSacubitril/Valsartan259$298,555
JardianceEmpagliflozin99$125,838
XareltoRivaroxaban132$120,277
MultaqDronedarone Hcl40$51,362
Repatha SureclickEvolocumab36$35,321
Ranolazine ErRanolazine286$27,848
FarxigaDapagliflozin Propanediol28$24,648
Irbesartan487$8,210
Torsemide610$8,154
Carvedilol1,026$8,133
Ezetimibe376$7,724
Praluent PenAlirocumab14$7,093
Atorvastatin Calcium612$6,233
Hydralazine Hcl293$5,766

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$413$684,917629 claims
NovartisEntresto$1,552$298,555259 claims
Boehringer IngelheimJardiance$734$125,83899 claims
Johnson & JohnsonXarelto$1,014$120,277132 claims
Sanofi-aventis U.S. LLCMultaq$522$51,36240 claims
AstraZenecaFarxiga$314$24,64828 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few cardiology providers in Arkansason file to place this against a meaningful peer group, so we don't.

Other cardiology in Fort Smith

Where these figures come from

Is this you, or does something look wrong? →